CN104856965B - A kind of freeze drying process of injection thymic peptide - Google Patents
A kind of freeze drying process of injection thymic peptide Download PDFInfo
- Publication number
- CN104856965B CN104856965B CN201510288309.XA CN201510288309A CN104856965B CN 104856965 B CN104856965 B CN 104856965B CN 201510288309 A CN201510288309 A CN 201510288309A CN 104856965 B CN104856965 B CN 104856965B
- Authority
- CN
- China
- Prior art keywords
- temperature
- injection
- sample
- freeze
- peptide solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention provides a kind of freeze drying process of injection thymic peptide, include the following steps：By the greenhouse cooling of thymus peptide solution sample to the first temperature, first temperature≤35 DEG C；Under conditions of first temperature, by thymus peptide solution sample pre-freeze under vacuum；After vacuum degree less than after 500ubar, the thymus peptide solution sample after pre-freeze is warming up to second temperature, the second temperature is higher than 15 DEG C；The temperature of thymus peptide solution sample is down to third temperature by the second temperature again, the third temperature is not higher than 40 DEG C；Thymus peptide solution sample is warming up to the 4th temperature by the third temperature again, is kept the temperature under conditions of four temperature, injection thymic peptide sample is obtained, the 4th temperature is not less than 40 DEG C.Compared with prior art, the injection thymic peptide sample that the present invention obtains has preferable solubility, and it is 3s that the time is averagely redissolved in embodiment 1, and it is 2s that the time is averagely redissolved under the conditions of shaking up.
Description
Technical field
The present invention relates to technical field of pharmaceuticals more particularly to a kind of freeze drying process of injection thymic peptide.
Background technology
Thymic peptide also known as thymosin extrasin or thymic factor are less than by the molecular weight extracted in health pig or calf thymus tissue
The polypeptide with physiological activity of 5000 dalton, the Thymosin alpha 1 that thymic peptide main active is made of 28 amino acid
(Tα1)。
Clinically thymic peptide is used to treat various primary or secondary T cell defect is sick, certain autoimmune diseases,
The auxiliary treatment of the low disease of various cellular immune functions and tumour specifically includes various serious hepatitis, chronic active liver
Scorching, chronic persistant hepatitis and hepatic sclerosis etc.；Herpes zoster, genital herpes, condyloma acuminatum etc.；3. bronchitis, bronchus
Asthma, pulmonary tuberculosis, prevention infection of the upper respiratory tract etc.；Various malignant tumour early periods and chemotherapy, radiotherapy, which shares, to be used in combination；Lupus erythematosus,
Rheumatic and atrophic diseases, ankylosing spondylitis, Guillain Barre syndrome etc.；Alpastic anemia, leukaemia, blood are small
Plate reduces disease etc.；7. viral keratitis, viral conjunctivitis, allergic rhinitis etc.；Senile early ageing, Woman climacteric synthesis
Sign etc.；Multiple furuncle and skin of face acne etc., psoriasis, lichen planus, squamous cell carcinoma and epithelium seborrheic keratosis etc.；Children
Congenital immune deficiency disease etc..
Existing thymic peptide administering mode includes subcutaneously or intramuscularly injecting and taking orally.Injection thymic peptide is usually by being lyophilized
Thymus peptide solution obtains, and injection thymic peptide lyophilized technique includes in the prior art：The glass bottle for being loaded with liquid is pushed into vacuum
In freeze drier；Products temperature is down to -40 DEG C or less to start to vacuumize, pre-freeze about 240min；Wait for that vacuum degree is less than
150ubar rises to 40 DEG C from -40 DEG C or less, period about 1800min with the speed of 3 DEG C/h；About 400min is kept the temperature at 40 DEG C；It closes
Vacuum pump is closed, vacuum, tamponade, outlet are stopped.The injection thymic peptide finished product solubility that this lyophilized technique obtains is poor, 20mg's
Sample is lyophilized, the average redissolution time of 2mL waters for injection is added as 72s, the redissolution time under the conditions of shaking up is 48s.
Invention content
The purpose of the present invention is to provide a kind of freeze drying process of injection thymic peptide, method provided by the invention is lyophilized
It is good that the injection thymic peptide finished product arrived redissolves performance.
The present invention provides a kind of freeze drying process of injection thymic peptide, include the following steps：
By the greenhouse cooling of thymus peptide solution sample to the first temperature, first temperature≤- 35 DEG C；
Under conditions of first temperature, by thymus peptide solution sample pre-freeze under vacuum；
After vacuum degree less than after 500ubar, the thymus peptide solution sample after pre-freeze is warming up to second temperature, described second
Temperature is higher than -15 DEG C；
The temperature of thymus peptide solution sample is down to third temperature by the second temperature again, the third temperature is not high
In -40 DEG C；
Thymus peptide solution sample is warming up to the 4th temperature by the third temperature again, is protected under conditions of four temperature
Temperature, obtains injection thymic peptide sample, and the 4th temperature is not less than 40 DEG C.
Preferably, the time of the pre-freeze is 120min~180min.
Preferably, the vacuum degree of the pre-freeze is 50~150ubar.
Preferably, the heating rate for being warming up to second temperature is 3 DEG C/h~7 DEG C/h.
Preferably, the second temperature is -15 DEG C~0 DEG C.
Preferably, the time that the second temperature is down to third temperature is preferably 300min~600min.
Preferably, the third temperature is -50 DEG C~-40 DEG C.
Preferably, the time that the third temperature is warming up to the 4th temperature is 800~1000min.
Preferably, the 4th temperature is 40 DEG C~50 DEG C.
Preferably, the time of the heat preservation is 120 DEG C~180 DEG C.
The present invention provides a kind of freeze drying process of injection thymic peptide, include the following steps：By thymus peptide solution sample
Greenhouse cooling to the first temperature, first temperature≤- 35 DEG C；Under conditions of first temperature, by thymus peptide solution
Sample pre-freeze under vacuum；After vacuum degree less than after 500ubar, the thymus peptide solution sample after pre-freeze is warming up to second
Temperature, the second temperature are higher than -15 DEG C；The temperature of thymus peptide solution sample is down to third temperature by the second temperature again
Degree, the third temperature are not higher than -40 DEG C；Thymus peptide solution sample is warming up to the 4th temperature by the third temperature again,
It is kept the temperature under conditions of 4th temperature, obtains injection thymic peptide sample, the 4th temperature is not less than 40 DEG C.With prior art phase
Than the injection thymic peptide sample that method provided by the invention obtains has preferable solubility, the experiment of the embodiment of the present invention
The result shows that the time of averagely being redissolved under conditions of not shaking for the injection thymic peptide sample that the present invention obtains is 3s, shake up
Under the conditions of averagely redissolve the time be 2s.
Moreover, injection thymic peptide sample no sample atrophy phenomenon that method provided by the invention obtains and cellular sample
Occur, ensure that the quality of product in the term of validity.Method provided by the invention makes injection thymic peptide medication safer, suitable
Industrial mass production.
Specific implementation mode
The present invention provides a kind of freeze drying process of injection thymic peptide, include the following steps：
By the greenhouse cooling of thymus peptide solution sample to the first temperature, first temperature≤- 35 DEG C；
Under conditions of first temperature, by thymus peptide solution sample pre-freeze under vacuum；
After vacuum degree less than after 500ubar, the thymus peptide solution sample after pre-freeze is warming up to second temperature, described second
Temperature is higher than -15 DEG C；
The temperature of thymus peptide solution sample is down to third temperature by the second temperature again, the third temperature is not high
In -40 DEG C；
Thymus peptide solution sample is warming up to the 4th temperature by the third temperature again, is protected under conditions of four temperature
Temperature, obtains injection thymic peptide sample, and the 4th temperature is not less than 40 DEG C.
Compared with prior art, the injection thymic peptide sample that method provided by the invention obtains has preferable redissolve
Property.Moreover, injection thymic peptide sample no sample atrophy phenomenon and cellular sample that method provided by the invention obtains occur,
It ensure that the quality of product in the term of validity.Method provided by the invention makes injection thymic peptide medication safer, suitable for industry
Change and produces in enormous quantities.
The temperature of thymus peptide solution sample is down to the first temperature, first temperature≤- 35 DEG C by the present invention.In the present invention
Embodiment in, specifically thymus peptide solution sample can be lyophilized in vacuum freeze drier, prepare injection thymic peptide
Finished product.In the present invention, first temperature is preferably -50 DEG C~-35 DEG C, more preferably -45 DEG C~-40 DEG C.In the present invention
In, the mass concentration of the thymus peptide solution is preferably 5mg/mL~20mg/mL, and more preferably 8mg/mL~15mg/mL is optimal
It is selected as 10mg/mL~15mg/mL.The present invention does not have the source of the thymus peptide solution special limitation, using this field skill
Thymus peptide solution known to art personnel.In the present invention, the rate of temperature fall for being cooled to the first temperature be preferably 13~
17℃/h。
After being cooled to the first temperature, the present invention is under conditions of first temperature, by thymus peptide solution sample in vacuum
Under the conditions of pre-freeze.In an embodiment of the present invention, after being cooled to the first temperature, it can specifically open vacuum pump and start to vacuumize,
Carry out pre-freeze.In the present invention, the vacuum degree of the pre-freeze is preferably 800ubar；The time of the pre-freeze is preferably 120min
~180min, more preferably 135min~165min, most preferably 145min~155min.In an embodiment of the present invention, exist
During pre-freeze, preferably continue to cool down with above-mentioned rate of temperature fall, until pre-freeze process terminates.
After vacuum degree less than after 500ubar, the thymus peptide solution sample after pre-freeze is warming up to second temperature, described second
Temperature is higher than -15 DEG C.The present invention is preferably when vacuum degree is down to 200ubar~500ubar, by the thymus peptide solution sample after pre-freeze
Product are warming up to second temperature, more preferably 300ubar~450ubar, more preferably 350ubar~400ubar.In the present invention
In, the second temperature is preferably -15 DEG C~0 DEG C, more preferably -10 DEG C~-5 DEG C；The heating for being warming up to second temperature
Rate is preferably 3 DEG C/h~7 DEG C/h, more preferably 4 DEG C/h~6 DEG C/h, most preferably 5 DEG C/h.In the present invention, the heating
Time to second temperature is preferably 500min~700min, more preferably 550min~650min, most preferably 600min.
After being warming up to second temperature, the temperature of thymus peptide solution sample is down to third by the present invention by the second temperature again
Temperature, the third temperature are not higher than -40 DEG C.In the present invention, the third temperature is preferably -50 DEG C~-40 DEG C, more preferably
For -48 DEG C~-42 DEG C, most preferably -45 DEG C；The time that the second temperature is cooled to third temperature be preferably 300min~
600min, more preferably 320min~500min, most preferably 350min~400min.In the present invention, the second temperature
During being cooled to third temperature, vacuum degree is preferably smaller than 800ubar.
After being cooled to third temperature, thymus peptide solution sample is warming up to the 4th temperature by the present invention by the third temperature again
Degree, keeps the temperature under conditions of four temperature, obtains injection thymic peptide sample, and the 4th temperature is not less than 40 DEG C.In this hair
In bright, during the third temperature is warming up to the 4th temperature, vacuum degree is preferably smaller than 200ubar.In the present invention, described
4th temperature is preferably 40 DEG C~50 DEG C, more preferably 42 DEG C~48 DEG C, most preferably 45 DEG C；The third temperature is warming up to
The time of four temperature is preferably 600~800min.In the present invention, the time of the heat preservation is preferably 120min~180min,
More preferably 135min~165min, most preferably 140min~150min；The vacuum degree of the heat preservation is preferably 50~
150ubar。
The present invention provides a kind of freeze drying process of injection thymic peptide, include the following steps：By thymus peptide solution sample
Greenhouse cooling to the first temperature, first temperature≤- 35 DEG C；Under conditions of first temperature, by thymus peptide solution
Sample pre-freeze under vacuum；After vacuum degree less than after 500ubar, the thymus peptide solution sample after pre-freeze is warming up to second
Temperature, the second temperature are higher than -15 DEG C；The temperature of thymus peptide solution sample is down to third temperature by the second temperature again
Degree, the third temperature are not higher than -40 DEG C；Thymus peptide solution sample is warming up to the 4th temperature by the third temperature again,
It is kept the temperature under conditions of 4th temperature, obtains injection thymic peptide sample, the 4th temperature is not less than 40 DEG C.With prior art phase
Than the injection thymic peptide sample that method provided by the invention obtains has preferable solubility, the experiment of the embodiment of the present invention
The result shows that the time of averagely being redissolved under conditions of not shaking for the injection thymic peptide sample that the present invention obtains is 3s, shake up
Under the conditions of averagely redissolve the time be 2s.
Moreover, injection thymic peptide sample no sample atrophy phenomenon that method provided by the invention obtains and cellular sample
Occur, ensure that the quality of product in the term of validity.Method provided by the invention makes injection thymic peptide medication safer, suitable
Industrial mass production.
In order to further illustrate the present invention, with reference to embodiment to the freeze-drying side of injection thymic peptide provided by the invention
Method is described in detail, but cannot they be interpreted as limiting the scope of the present invention.
Embodiment 1
By the thymus peptide solution of prepared a concentration of 10mg/mL filling 1000, loading amount 2.0mL, half tamponade；
By in the glass bottle push-in vacuum freeze drier for filling liquid, products temperature is down to -35 DEG C, starts to vacuumize
Vacuum degree is less than 800ubar, pre-freeze 120min；
After vacuum degree less than after 500ubar, products temperature is risen to -15 DEG C from -35 DEG C with the heating rate of 3 DEG C/h, week
Phase about 350min；
Products temperature is down to -40 DEG C again, cool down used time about 350min；
Products temperature is finally warming up to 40 DEG C, 120min is kept the temperature under conditions of 40 DEG C；
After the completion of heat preservation, vacuum pump is closed, stops vacuum tamponade, outlet, obtains injection thymic peptide finished product.
The quality for the injection thymic peptide finished product that the present invention detects, observation sample have the ratio of atrophy, sample appearance
There is cellular ratio, the average redissolution time of addition 2mL waters for injection and injection 2mL waters for injection shake up into sample
The time is averagely redissolved, the results are shown in Table 1, and table 1 is the embodiment of the present invention and the experimental result that comparative example obtains.
Embodiment 2
By the thymus peptide solution of prepared a concentration of 10mg/mL filling 1000, loading amount 2.0mL, half tamponade；
By in the glass bottle push-in vacuum freeze drier for filling liquid, products temperature is down to -35 DEG C, starts to vacuumize
Vacuum degree is less than 800ubar, pre-freeze 180min；
After vacuum degree less than after 500ubar, products temperature is risen to -15 DEG C from -35 DEG C with the heating rate of 7 DEG C/h, week
Phase about 172min；
Products temperature is down to -40 DEG C again, cool down used time about 500min；
Products temperature is finally warming up to 45 DEG C, 150min is kept the temperature under conditions of 45 DEG C；
After the completion of heat preservation, vacuum pump is closed, stops vacuum tamponade, outlet, obtains injection thymic peptide finished product.
The quality for the injection thymic peptide finished product that the present invention detects, observation sample have the ratio of atrophy, sample appearance
There is cellular ratio, the average redissolution time of addition 2mL waters for injection and injection 2mL waters for injection shake up into sample
The time is averagely redissolved, the results are shown in Table 1, and table 1 is the embodiment of the present invention and the experimental result that comparative example obtains.
Embodiment 3
By the thymus peptide solution of prepared a concentration of 10mg/mL filling 1000, loading amount 2.0mL, half tamponade；
By in the glass bottle push-in vacuum freeze drier for filling liquid, products temperature is down to -35 DEG C, starts to vacuumize small
In 800ubar, pre-freeze 150min；
After vacuum degree less than after 500ubar, products temperature is risen to -15 DEG C from -35 DEG C with the heating rate of 5 DEG C/h, week
Phase about 240min；
Products temperature is down to -40 DEG C again, cool down used time about 600min；
Products temperature is finally warming up to 42 DEG C, 180min is kept the temperature under conditions of 45 DEG C；
After the completion of heat preservation, vacuum pump is closed, stops vacuum tamponade, outlet, obtains injection thymic peptide finished product.
The quality for the injection thymic peptide finished product that the present invention detects, observation sample have the ratio of atrophy, sample appearance
There is cellular ratio, the average redissolution time of addition 2mL waters for injection and injection 2mL waters for injection shake up into sample
The time is averagely redissolved, the results are shown in Table 1, and table 1 is the embodiment of the present invention and the experimental result that comparative example obtains.
Comparative example
By the thymus peptide solution of prepared a concentration of 10mg/mL filling 1000, loading amount 2.0mL, half tamponade；
It will be loaded in the glass bottle push-in vacuum freeze drier of liquid, products temperature be down to -40 DEG C hereinafter, starting to take out
Vacuum, pre-freeze about 240min；
It waits for that vacuum degree is less than 150ubar, rises to 40 DEG C from -40 DEG C or less with the heating rate of 3 DEG C/h, the period is about
1800min；
About 400min is kept the temperature at 40 DEG C, vacuum pump is closed after heat preservation, stops vacuum, tamponade, outlet obtain injection thymus gland
Peptide finished product.
The quality for the injection thymic peptide finished product that the present invention detects, observation sample have the ratio of atrophy, sample appearance
There is cellular ratio, the average redissolution time of addition 2mL waters for injection and injection 2mL waters for injection shake up into sample
The time is averagely redissolved, the results are shown in Table 1, and table 1 is the embodiment of the present invention and the experimental result that comparative example obtains.
The experimental result that 1 embodiment of the present invention of table and comparative example obtain
| Inspection item | Comparative example | Embodiment 1 | Embodiment 2 | Embodiment 3 |
| Sample number after freeze-drying | 1000 | 1000 | 1000 | 1000 |
| There is the sample size of atrophy | 72 | 0 | 0 | 0 |
| Appearance has cellular sample size | 421 | 0 | 0 | 0 |
| Averagely redissolve the time (second) | 72 | 3 | 8 | 5 |
| The average redissolution time under the conditions of shaking up | 48 | 2 | 5 | 3 |
As can be seen from Table 1, the injection thymic peptide finished product that method provided by the invention obtains without atrophy, without cellular sample
Product, and averagely the redissolution time substantially reduces.
As can be seen from the above embodiments, the present invention provides a kind of freeze drying process of injection thymic peptide, including it is following
Step：By the greenhouse cooling of thymus peptide solution sample to the first temperature, first temperature≤- 35 DEG C；In first temperature
Under conditions of, by thymus peptide solution sample pre-freeze under vacuum；After vacuum degree is less than 500ubar, by the chest after pre-freeze
Gland peptide solution sample is warming up to second temperature, and the second temperature is higher than -15 DEG C；Again by the temperature of thymus peptide solution sample by institute
It states second temperature and is down to third temperature, the third temperature is not higher than -40 DEG C；Again by thymus peptide solution sample by the third temperature
Degree is warming up to the 4th temperature, is kept the temperature under conditions of four temperature, obtains injection thymic peptide sample, the 4th temperature is not low
In 40 DEG C.Compared with prior art, the injection thymic peptide sample that method provided by the invention obtains has preferable solubility,
No sample atrophy phenomenon and cellular sample occur in obtained injection thymic peptide finished product, ensure that the matter of product in the term of validity
Amount.Method provided by the invention makes injection thymic peptide medication safer, suitable for industrial mass production.
The above is only a preferred embodiment of the present invention, it is noted that for the ordinary skill people of the art
For member, various improvements and modifications may be made without departing from the principle of the present invention, these improvements and modifications are also answered
It is considered as protection scope of the present invention.
Claims (1)
1. a kind of freeze drying process of injection thymic peptide, includes the following steps：
By the greenhouse cooling of thymus peptide solution sample to the first temperature, first temperature is -50 DEG C~-35 DEG C；
Under conditions of first temperature, by thymus peptide solution sample, pre-freeze, the time of the pre-freeze are under vacuum
120min~180min；
After vacuum degree less than after 500 μ bar, the thymus peptide solution sample after pre-freeze is warming up to second temperature, it is described to be warming up to the
The heating rate of two temperature is 3 DEG C/h~7 DEG C/h；The second temperature is -15 DEG C~0 DEG C；
The temperature of thymus peptide solution sample is down to third temperature by the second temperature again, the second temperature is down to third temperature
The time of degree is 300min~600min；The third temperature is -50 DEG C~-40 DEG C；
Thymus peptide solution sample is warming up to the 4th temperature by the third temperature again, keeps the temperature, obtains under conditions of four temperature
To injection thymic peptide sample, the time that the third temperature is warming up to the 4th temperature is 800~1000min；4th temperature
Degree is 40 DEG C~50 DEG C；The time of the heat preservation is 120min~180min.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510288309.XA CN104856965B (en) | 2015-05-29 | 2015-05-29 | A kind of freeze drying process of injection thymic peptide |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510288309.XA CN104856965B (en) | 2015-05-29 | 2015-05-29 | A kind of freeze drying process of injection thymic peptide |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104856965A CN104856965A (en) | 2015-08-26 |
| CN104856965B true CN104856965B (en) | 2018-07-20 |
Family
ID=53903441
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510288309.XA Active CN104856965B (en) | 2015-05-29 | 2015-05-29 | A kind of freeze drying process of injection thymic peptide |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104856965B (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1712064A (en) * | 2004-06-23 | 2005-12-28 | 北京赛生药业有限公司 | Production of high-concentration thymic peptide solution and large-specification thymic peptide preparation |
| CN101934068A (en) * | 2010-09-26 | 2011-01-05 | 武汉华龙生物制药有限公司 | Preparation method of thymopetidum injection |
| CN102247319A (en) * | 2011-08-03 | 2011-11-23 | 海南中和药业有限公司 | Thymalfasin-containing medicinal composition and preparation method thereof |
| CN102762196A (en) * | 2009-11-24 | 2012-10-31 | 基立福疗法公司 | Lyophilization methods, compositions, and kits |
| CN102949356A (en) * | 2012-11-28 | 2013-03-06 | 天津红日药业股份有限公司 | Thymalfasin-containing freeze-dried preparation |
| CN104127863A (en) * | 2014-08-06 | 2014-11-05 | 北京美迪康信医药科技有限公司 | Thymosin-containing medicinal composition and preparation thereof |
-
2015
- 2015-05-29 CN CN201510288309.XA patent/CN104856965B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1712064A (en) * | 2004-06-23 | 2005-12-28 | 北京赛生药业有限公司 | Production of high-concentration thymic peptide solution and large-specification thymic peptide preparation |
| CN102762196A (en) * | 2009-11-24 | 2012-10-31 | 基立福疗法公司 | Lyophilization methods, compositions, and kits |
| CN101934068A (en) * | 2010-09-26 | 2011-01-05 | 武汉华龙生物制药有限公司 | Preparation method of thymopetidum injection |
| CN102247319A (en) * | 2011-08-03 | 2011-11-23 | 海南中和药业有限公司 | Thymalfasin-containing medicinal composition and preparation method thereof |
| CN102949356A (en) * | 2012-11-28 | 2013-03-06 | 天津红日药业股份有限公司 | Thymalfasin-containing freeze-dried preparation |
| CN104127863A (en) * | 2014-08-06 | 2014-11-05 | 北京美迪康信医药科技有限公司 | Thymosin-containing medicinal composition and preparation thereof |
Non-Patent Citations (1)
| Title |
|---|
| 胸腺肽剂型的研究进展;张庆云等;《武警医学院学报》;20080131;第17卷(第1期);65-67 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104856965A (en) | 2015-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11660343B2 (en) | Viscosity-reducing excipient compounds for protein formulations | |
| EP2373293B2 (en) | Compositions with reduced dimer formation | |
| CN102144981B (en) | Gemcitabine hydrochloride lyophilized powder injection and preparation method thereof | |
| CN106063933B (en) | Universal vaccine freeze-drying protective agent and application thereof | |
| CN101249043B (en) | Applications of human growth hormone and human epidermal growth factor combination in beauty treatment | |
| RU2764630C2 (en) | Methods and compositions for preventing or minimizing epithelial-mesenchymal transition | |
| KR20190117631A (en) | Excipient Compounds for Protein Processing Treatment | |
| CN102670522A (en) | Pharmaceutical preparation containing recombinant human serum albumin-human granulocyte colony stimulating factor fusion protein and preparation thereof | |
| CN101693016B (en) | Universal pharmaceutical formulation for recombined human serum albumin fusion proteins for injection | |
| CN104856965B (en) | A kind of freeze drying process of injection thymic peptide | |
| TW201529097A (en) | Novel formulation for gonadotropins | |
| WO2016045530A1 (en) | Chlorogenic acid lyophilised powder for injection having high resolubility and high stability | |
| CN109172530B (en) | Medicine composition containing oxytocin and preparation method thereof | |
| CN112107678B (en) | Freeze-dried composition containing thymalfasin and preparation method thereof | |
| CN110974789B (en) | Fludarabine phosphate freeze-drying agent and preparation method thereof | |
| CN103230373A (en) | Dexlansoprazole freeze-drying powder for injection and preparation method thereof | |
| CN106913531B (en) | Mycophenolate mofetil freeze-dried composition and preparation method thereof | |
| CN101376022B (en) | Medicament composition containing defibrase modified by PEG | |
| CN107982261B (en) | Esomeprazole sodium freeze-dried powder and preparation method thereof | |
| CN109364030A (en) | A kind of injection bortezomib freeze-dried powder and its preparation process | |
| CN102342920B (en) | Pharmaceutical composition containing alarelin acetate and preparation method thereof | |
| CN113797170A (en) | Fluorouracil freeze-dried preparation for injection and preparation method thereof | |
| CN116808178A (en) | Freeze-drying process of high-purity urotropin for injection | |
| CN115518045A (en) | Esomeprazole sodium for injection | |
| CN107753443A (en) | A kind of double auxiliary material injection diammonium glycyrrhizinate freeze dried powder ampoul agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| EXSB | Decision made by sipo to initiate substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: Yueyang economic and Technological Development Zone Industrial Park Road 414100 Hunan Kanwan chisi city in Yueyang Province Applicant after: Hunan Kelun Pharmaceutical Co., Ltd. Address before: Chengguan town of Yueyang County in Hunan province 414000 Yueyang Rong Road (county eco industrial park No. 3) Applicant before: Hunan Kelun Pharmaceutical Co., Ltd. |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |